Last reviewed · How we verify
Denosumab De-escalation
Denosumab de-escalation is a treatment strategy that reduces the dose or frequency of denosumab (a RANKL inhibitor) to minimize long-term adverse effects while maintaining therapeutic benefit in bone disease.
Denosumab de-escalation is a treatment strategy that reduces the dose or frequency of denosumab (a RANKL inhibitor) to minimize long-term adverse effects while maintaining therapeutic benefit in bone disease. Used for Osteoporosis management with reduced dosing, Bone metastases with de-escalated dosing to reduce adverse effects.
At a glance
| Generic name | Denosumab De-escalation |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | RANKL inhibitor monoclonal antibody de-escalation strategy |
| Target | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Bone Metabolism, Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), thereby suppressing osteoclast formation and bone resorption. De-escalation involves lowering the dose or extending dosing intervals to reduce cumulative exposure and associated risks such as osteonecrosis of the jaw, atypical fractures, and hypocalcemia, while preserving efficacy in conditions like osteoporosis and bone metastases.
Approved indications
- Osteoporosis management with reduced dosing
- Bone metastases with de-escalated dosing to reduce adverse effects
Common side effects
- Osteonecrosis of the jaw
- Atypical fractures
- Hypocalcemia
- Infection
Key clinical trials
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (PHASE3)
- Step-down Therapy After Long-term Osteoporosis Treatment (PHASE4)
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (PHASE4)
- Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Denosumab De-escalation CI brief — competitive landscape report
- Denosumab De-escalation updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI